Austen B, Christodoulou G, Terry J E
Neurodegeneration Unit, Department of Surgery, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, U.K.
J Nutr Health Aging. 2002;6(6):377-82.
This review paper discusses potential relationships between Cholesterol levels, the therapeutic use of Statins and the risk of Alzheimer s Disease. Comparisons have also been made between the Western populations and Oriental populations. Epidemiological studies have shown that statins, which reduce the levels of plasma cholesterol by inhibiting the enzyme 3 hydroxy-3methylglutaryl-coenzyme A (HMGCoA) reductase, reduce the risk of Alzheimer s disease by up to 70%. Further research is required to determine whether cholesterol levels have a direct, causative, or indirect relationship with Alzheimer disease. Also, it is not clear why some statins reduce the prevalence of AD and others do not. Statins may have an affect on other AD risk factors, or act by mechanisms which are independent of their effects on cholesterol levels?
这篇综述论文讨论了胆固醇水平、他汀类药物的治疗用途与阿尔茨海默病风险之间的潜在关系。还对西方人群和东方人群进行了比较。流行病学研究表明,他汀类药物通过抑制3-羟基-3-甲基戊二酰辅酶A(HMGCoA)还原酶来降低血浆胆固醇水平,可将阿尔茨海默病的风险降低多达70%。需要进一步研究以确定胆固醇水平与阿尔茨海默病之间是直接、因果还是间接关系。此外,尚不清楚为什么有些他汀类药物能降低阿尔茨海默病的患病率而有些则不能。他汀类药物可能对其他阿尔茨海默病风险因素有影响,或者通过与其对胆固醇水平的影响无关的机制起作用?